168 related articles for article (PubMed ID: 28324272)
1. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.
Sakamaki A; Watanabe T; Abe S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
Clin J Gastroenterol; 2017 Jun; 10(3):261-264. PubMed ID: 28324272
[TBL] [Abstract][Full Text] [Related]
2. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
[TBL] [Abstract][Full Text] [Related]
4. [Avoidance of platelet transfusion with readministration of lusutrombopag before radiofrequency ablation in hepatocellular carcinoma:a case report].
Kotani S; Kohge N; Tsukano K; Ogawa S; Yamanouchi S; Kusunoki R; Aimi M; Miyaoka Y; Fujishiro H
Nihon Shokakibyo Gakkai Zasshi; 2017; 114(10):1853-1859. PubMed ID: 28978885
[TBL] [Abstract][Full Text] [Related]
5. Lusutrombopag: First Global Approval.
Kim ES
Drugs; 2016 Jan; 76(1):155-8. PubMed ID: 26666417
[TBL] [Abstract][Full Text] [Related]
6. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
[TBL] [Abstract][Full Text] [Related]
7. Relationship between response to lusutrombopag and splenic volume.
Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
Tsuji Y; Kawaratani H; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Takaya H; Shimozato N; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
Dig Dis; 2020; 38(4):329-334. PubMed ID: 31655803
[TBL] [Abstract][Full Text] [Related]
10. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
[TBL] [Abstract][Full Text] [Related]
11. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization.
Fujita M; Abe K; Hayashi M; Okai K; Takahashi A; Ohira H
Fukushima J Med Sci; 2017 Dec; 63(3):165-171. PubMed ID: 29142151
[TBL] [Abstract][Full Text] [Related]
12. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
[TBL] [Abstract][Full Text] [Related]
13. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.
Shirley M; McCafferty EH; Blair HA
Drugs; 2019 Oct; 79(15):1689-1695. PubMed ID: 31529283
[TBL] [Abstract][Full Text] [Related]
14. A study on prevention of bleeding complications using lusutrombopag for safe RFA in patients with hepatocellular carcinoma with low platelet counts: prospective observational study.
Yoshida H; Ohki T; Kanezaki M; Teratani T; Sato S; Obi S; Sato T; Akamatsu M; Uchino K; Taniguchi H
BMC Gastroenterol; 2023 Jul; 23(1):250. PubMed ID: 37488476
[TBL] [Abstract][Full Text] [Related]
15. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
Biolato M; Vitale F; Marrone G; Miele L; Grieco A
Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
[TBL] [Abstract][Full Text] [Related]
16. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma.
Alkhouri N; Imawari M; Izumi N; Osaki Y; Ochiai T; Kano T; Bentley R; Trevisani F
Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2600-2608.e1. PubMed ID: 32205226
[TBL] [Abstract][Full Text] [Related]
17. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.
Wada N; Uojima H; Satoh T; Okina S; Iwasaki S; Shao X; Takiguchi H; Arase Y; Itokawa N; Atsukawa M; Miyazaki K; Hidaka H; Kako M; Kagawa T; Iwakiri K; Horie R; Suzuki T; Koizumi W
Dig Dis; 2021; 39(3):234-242. PubMed ID: 32759604
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
[TBL] [Abstract][Full Text] [Related]
19. Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
Kaneko T; Takano Y; Ishibashi K
Medicine (Baltimore); 2021 Jan; 100(2):e24094. PubMed ID: 33466174
[TBL] [Abstract][Full Text] [Related]
20. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease:
Tanaka K; Baba T; Yoshida M; Iguchi M; Sonoyama T; Fukuhara T; Kano T
Curr Med Res Opin; 2022 Feb; 38(2):303-310. PubMed ID: 34904508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
